StockNews.com Begins Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)

Research analysts at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued on Sunday. The firm set a “buy” rating on the biotechnology company’s stock.

ADAP has been the subject of several other reports. Scotiabank lowered their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday, March 21st. HC Wainwright lowered their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Guggenheim reduced their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Finally, Wells Fargo & Company lowered their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $1.83.

Adaptimmune Therapeutics Stock Down 0.7 %

Shares of NASDAQ:ADAP opened at $0.26 on Friday. The firm has a market capitalization of $65.95 million, a PE ratio of -1.17 and a beta of 2.84. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The firm’s 50-day moving average is $0.47 and its two-hundred day moving average is $0.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. Analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Two Seas Capital LP purchased a new stake in shares of Adaptimmune Therapeutics during the 4th quarter worth approximately $7,992,000. Two Sigma Investments LP lifted its position in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 19,146 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Adaptimmune Therapeutics by 87.7% during the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 152,780 shares during the last quarter. Finally, Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after purchasing an additional 7,194,503 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.